This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Drugs

Stock Market Today: Stocks Rise Despite Home Sales Weaker Than Forecast

Stock Market Today: Stocks Rise Despite Home Sales Weaker Than Forecast

U.S. stock markets rise slightly on Friday despite U.S. home sales for September missing economists' forecasts and a sharp revision downward in August sales.

10/24/14 - 10:23 AM EDT

Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta

Biotech columnist Adam Feuerstein answers readers' questions about health care.

10/24/14 - 08:28 AM EDT

Try Jim Cramer's Action Alerts PLUS
October 24 Premarket Briefing: 10 Things You Should Know

October 24 Premarket Briefing: 10 Things You Should Know

U.S. stock futures decline; Amazon reports a wider-than-expected loss; Microsoft tops estimates; Ford to report earnings.

10/24/14 - 05:22 AM EDT

Eli Lilly Hit By Patent Expirations, Prescription Volume Plunges

  • Tickers in this article:
  • LLY

Eli Lilly lost exclusivity in high profile drugs like Cymbalta and Evista and generic competition brought down the volume of medications doctors prescribed.

10/23/14 - 09:51 AM EDT

J&J Sees 250,000 Ebola Vaccine Doses Ready for Trials By May

  • Tickers in this article:
  • JNJ

Johnson & Johnson plans to roll out an Ebola vaccine it is working on developing for clinical trials by May.

10/22/14 - 11:36 AM EDT

Will This Price Target Increase Help AbbVie (ABBV) Stock Today?

Will This Price Target Increase Help AbbVie (ABBV) Stock Today?

  • Tickers in this article:
  • ABBV

BMO Capital Markets raises its price target for AbbVie (ABBV) to $61 from $59 with an 'outperform' rating.

10/22/14 - 09:22 AM EDT

October 22 Premarket Briefing: 10 Things You Should Know

October 22 Premarket Briefing: 10 Things You Should Know

U.S. stock futures point lower; Yahoo! reports sharply better-than-expected earnings; Boeing and AT&T to post earnings reports; J&J to begin testing Ebola vaccine.

10/22/14 - 06:36 AM EDT

Ebola Stocks May Be Overpriced as Fundamentals Outweigh Fear

Ebola Stocks May Be Overpriced as Fundamentals Outweigh Fear

  • Tickers in this article:
  • IBIO
  • RAI

Ebola stocks have soared in recent weeks but a closer look at fundamentals may serve as a reality check for investors playing the story.

10/21/14 - 06:10 AM EDT

First Detailed Look at Celgene Crohn's Disease Pill Impresses

First Detailed Look at Celgene Crohn's Disease Pill Impresses

As a pill, Celgene's GED-031 (also known as mongersen) has the potential to become a preferred Crohn's therapy over injectable drugs like Abbvie's top-selling Humira.

10/20/14 - 10:56 AM EDT

Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents

Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents

Biotech columnist Adam Feuerstein answers readers' questions about health care.

10/17/14 - 07:05 AM EDT

AbbVie Kills Shire Merger, But Door Opens for Bristol-Myers Squibb?

AbbVie Kills Shire Merger, But Door Opens for Bristol-Myers Squibb?

Bristol-Myers Squibb once showed interest in Shire. With AbbVie out of the way, could deal talks between Bristol-Myers and Shire resume? Here's why a Bristol-Myers and Shire deal makes sense.

10/16/14 - 08:10 PM EDT

Ebola Patients May Have to Go Without Experimental Drugs in Trial

U.S. health officials reportedly want some Ebola patients to go without experimental treatments so they can compare their reactions to patients who do receive the drugs.

10/16/14 - 03:02 PM EDT

European Stocks Continue Downward Spiral as AbbVie Abandons Shire Deal

European stock indices resume their slide, with indices declining for the eighth consecutive daY.

10/16/14 - 08:12 AM EDT

October 16 Premarket Briefing: 10 Things You Should Know

October 16 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are falling sharply; Netflix's subscriber growth lags estimates; AbbVie drops takeover deal for Shire; Google to report earnings.

10/16/14 - 06:42 AM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs